Epistem announces successful completion of Genedrive® Indian clinical trials and regulatory submission

Epistem Holdings Plc, the personalised medicine and biotechnology company, announced the successful completion of its Genedrive® Indian clinical evaluation study and the regulatory submission with the Drug Controller General of India (DCGI) of its first test for the diagnosis of Tuberculosis and Rifampicin antibiotic resistance (TB). Epistem is now awaiting approval from the Indian regulator for a license to import and sell its first major infectious disease assay for TB, which is anticipated early in 2015.